Truist Financial Corp Macrogenics Inc Transaction History

Truist Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $585,440 - $1.02 Million	-28,572 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $82,131 - $143,590	-4,325 Reduced 13.15%	28,572 $911,000
Q4 2020 Feb 18, 2021	BUY	$19.41 - $26.0 $45,516 - $60,970	2,345 Added 7.68%	32,897 $752,000
Q3 2020 Nov 13, 2020	BUY	$24.69 - $31.6 $158,016 - $202,240	6,400 Added 26.5%	30,552 $770,000
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $103,370 - $292,480	24,152 New	24,152 $140,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.